Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP No. 89620X506
|
1
|
NAMES OF REPORTING PERSONS
|
Vivo Capital IX, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a) ☒
|
(b) ☐
|
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
Delaware
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
|
5
|
SOLE VOTING POWER
|
820,940 (1)
|
6
|
SHARED VOTING POWER
|
0
|
7
|
SOLE DISPOSITIVE POWER
|
820,940 (1)
|
8
|
SHARED DISPOSITIVE POWER
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
820,940 (1)
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
|
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
1.1% (2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
OO
|
|
(1)
|
The shares of common stock, no par value (the “Common
Stock”) of Trillium Therapeutics, Inc. (the “Issuer”) are held of record by Vivo Capital Fund IX, L.P. Vivo
Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P.
|
|
(2)
|
Based on 74,968,709 shares of Common Stock of the Issuer
outstanding as of January 27, 2020,which includes (i) 33,689,619 shares of Common Stock outstanding as of January 22, 2020, and
(ii) 41,279,090 shares of Common Stock issued in connection with the underwritten offering as of January 23, 2020 (including 5,547,272
shares of Common Stock issued pursuant to the exercise of underwriters’ over-allotment option), both of which numbers are
disclosed in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission (the “SEC”)
on January 23, 2020, which forms part of the Issuer’s Registration Statement on Form F-10 (File No. 333-222085).
|
CUSIP No. 89620X506
|
1
|
NAMES OF REPORTING PERSONS
|
Vivo Opportunity, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a) ☒
|
(b) ☐
|
3
|
SEC USE ONLY
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
Delaware
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH
|
5
|
SOLE VOTING POWER
|
3,679,060 (1)
|
6
|
SHARED VOTING POWER
|
0
|
7
|
SOLE DISPOSITIVE POWER
|
3,679,060 (1)
|
8
|
SHARED DISPOSITIVE POWER
|
0
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
3,679,060 (1)
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
|
☐
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
4.9 % (2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
OO
|
|
(1)
|
The shares of Common Stock are held of record by Vivo Opportunity
Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P.
|
|
(2)
|
Based on 74,968,709 shares of Common Stock of the Issuer
outstanding as of January 27, 2020,which includes (i) 33,689,619 shares of Common Stock outstanding as of January 22, 2020, and
(ii) 41,279,090 shares of Common Stock issued in connection with the underwritten offering as of January 23, 2020 (including 5,547,272
shares of Common Stock issued pursuant to the exercise of underwriters’ over-allotment option), both of which numbers are
disclosed in the prospectus supplement filed by the Issuer with the SEC on January 23, 2020, which forms part of the Issuer’s
Registration Statement on Form F-10 (File No. 333-222085).
|
|
Item 1. (a)
|
Name of Issuer:
|
Trillium
Therapeutics, Inc.
|
(b)
|
Address of Issuer's
Principal Executive Offices:
|
2488
Dunwin Drive
Mississauga,
Ontario L5L 1J9
Canada
|
Item 2. (a)
|
Name of Person Filing:
|
This
Schedule 13G is filed jointly by Vivo Capital IX, LLC and Vivo Opportunity, LLC. Vivo Capital IX, LLC and Vivo Opportunity, LLC
have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which
they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange
Act of 1934, as amended.
|
(b)
|
Address of Principal
Business Office or, if None, Residence:
|
192
Lytton Avenue, Palo Alto, CA 94301
Vivo
Capital IX, LLC is a Delaware limited liability company.
Vivo
Opportunity, LLC is a Delaware limited liability company.
|
(d)
|
Title of Class
of Securities:
|
Common
Stock, no par value
89620X506
|
Item 3.
|
If This Statement is Filed Pursuant to §§
240.13d-1(b), or 240.13d-2(b) or (c),
Check Whether the Person Filing is a:
|
|
(a)
|
☐
|
Broker or dealer registered under Section 15 of the Act.
|
|
|
|
|
|
(b)
|
☐
|
Bank as defined in Section 3(a)(6) of the Act.
|
|
|
|
|
|
(c)
|
☐
|
Insurance company as defined in Section 3(a)(19) of the Act.
|
|
|
|
|
|
(d)
|
☐
|
Investment company registered under Section 8 of the Investment Company Act of 1940.
|
|
|
|
|
|
(e)
|
☐
|
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
☐
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
☐
|
A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
|
|
|
|
|
|
(h)
|
☐
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
|
|
|
|
|
|
(i)
|
☐
|
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
|
|
(j)
|
☐
|
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
|
(k)
|
☐
|
Group, in accordance with § 240.13d-1(b)(l)(ii)(K).
|
If filing as a non-U.S. institution
in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:
________________
Not Applicable.
|
(a)
|
Amount beneficially
owned:
|
(1)
Vivo Capital IX, LLC
The
820,940 shares of Common Stock are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of
Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen
Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership
of such shares.
(2)
Vivo Opportunity, LLC
The
3,679,060 shares of Common Stock are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner
of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung
and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims
beneficial ownership of such shares.
Vivo
Capital IX, LLC: 1.1%
Vivo
Opportunity, LLC: 4.9%
|
(c)
|
Number of shares
as to which such person has:
|
|
(i)
|
Sole
power to vote or to direct the vote:
|
Vivo
Capital IX, LLC: 820,940 shares
Vivo
Opportunity, LLC: 3,679,060 shares
|
(ii)
|
Shared
power to vote or to direct the vote: 0
|
|
(iii)
|
Sole
power to dispose or to direct the disposition of:
|
Vivo
Capital IX, LLC: 820,940 shares
Vivo
Opportunity, LLC: 3,679,060 shares
|
(iv)
|
Shared
power to dispose of or to direct the disposition of: 0
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
Not
Applicable.
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
Not
Applicable.
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported
on by the Parent Holding Company or Control Person.
|
Not
Applicable.
|
Item 8.
|
Identification and Classification of Members of the Group.
|
Not
applicable.
|
Item 9.
|
Notice of Dissolution of Group.
|
Not
applicable.
By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under §240.14a11.
SIGNATURE
After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
|
Vivo Capital IX, LLC
|
|
|
|
February 3, 2020
|
|
(Date)
|
|
|
|
/s/ Albert Cha
|
|
(Signature)
|
|
|
|
Managing Member
|
|
(Title)
|
|
|
|
Vivo Opportunity, LLC
|
|
|
|
February 3, 2020
|
|
(Date)
|
|
|
|
/s/ Albert Cha
|
|
(Signature)
|
|
|
|
Managing Member
|
|
(Title)
|
7